Castracane V D, Gimpel T, Goldzieher J W
Department of Obstetrics & Gynecology, Texas Tech University Health Sciences Center, Amarillo 79106, USA.
Contraception. 1995 Dec;52(6):371-6. doi: 10.1016/0010-7824(95)00229-4.
Women may continue to use oral contraceptives (OCs) into their 40's and 50's, but to date no method has been evaluated to ascertain their ovarian status, i.e., whether fertility and estrogen production have diminished sufficiently so they could be safely switched to hormonal replacement therapy. A group of 12 postmenopausal women who had been, for long periods of time, on a regimen of 3 back-to-back packages (i.e., 63 days on, 7 days off) of low-dose oral contraceptives have been studied. Secondly, a group of 9 perimenopausal women aged 36 to 47 were examined in the same manner. The third group consisted of early reproductive age women (arbitrarily divided into subsets aged 17-25 and 26-35 using low-dose OCs in the customary regimen) as normal controls. Blood samples were obtained on the last day of a pill cycle and at 7 days off the pill. In some menopausal women, blood samples were obtained at both 7 and 14 days off OCs. Serum was assayed by RIA for estradiol, FSH and LH. As expected in the young reproductive age women, estradiol levels increase at one week off the pill, together with a rebound in FSH and LH to follicular phase levels. In the perimenopausal group, there was a sharp distinction based on age. The women over 40 showed a more marked rise in FSH while those aged 36-40 showed a distinctly lesser response. Estradiol levels were variable, but tended to show some age grouping. Little diagnostic separation was observed for LH. In postmenopausal women, FSH levels were not always elevated at one week post-pill, and even in a second trial with sampling at one and two weeks off the OC, not all postmenopausal women showed a "menopausal" increase in FSH. The more uniform feature was that estradiol levels never increased above basal values. The study found that serum estradiol levels increase after a week off the pill in controls, but are unchanged at one and two weeks in the menopausal group. FSH levels rebound normally in reproductive age women and usually, but not always, increase substantially in postmenopausal women. After two weeks off OCs, an increased FSH and/or no change in basal estradiol levels is strong evidence that it is now safe (contraceptively speaking) to switch from OCs to standard hormone replacement regimens.
女性在40多岁和50多岁时仍可继续使用口服避孕药(OCs),但迄今为止,尚未评估任何方法来确定她们的卵巢状态,即生育能力和雌激素分泌是否已充分下降,以便她们能够安全地转而采用激素替代疗法。对一组12名绝经后女性进行了研究,她们长期采用连续服用3个包装(即服用63天,停药7天)的低剂量口服避孕药的方案。其次,以同样的方式检查了一组9名年龄在36至47岁之间的围绝经期女性。第三组由育龄期早期女性(任意分为17 - 25岁和26 - 35岁两个亚组,采用常规方案服用低剂量OCs)作为正常对照。在服药周期的最后一天以及停药7天时采集血样。在一些绝经后女性中,在停药7天和14天时均采集了血样。通过放射免疫分析法(RIA)检测血清中的雌二醇、促卵泡激素(FSH)和促黄体生成素(LH)。正如年轻育龄期女性所预期的那样,停药一周后雌二醇水平升高,同时FSH和LH反弹至卵泡期水平。在围绝经期组中,根据年龄有明显差异。40岁以上的女性FSH升高更为明显,而36 - 40岁的女性反应明显较小。雌二醇水平各不相同,但倾向于呈现一定的年龄分组。LH方面几乎没有观察到诊断性差异。在绝经后女性中,停药一周时FSH水平并非总是升高,甚至在停药一周和两周时进行的第二次采样试验中,并非所有绝经后女性的FSH都出现“绝经”性升高。更一致的特征是雌二醇水平从未升高至基础值以上。研究发现,对照组停药一周后血清雌二醇水平升高,但绝经组在停药一周和两周时无变化。育龄期女性FSH水平正常反弹,绝经后女性通常(但并非总是)大幅升高。停药两周后,FSH升高和/或基础雌二醇水平无变化是从口服避孕药转而采用标准激素替代方案现在安全(从避孕角度而言)的有力证据。